We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.65 | 0.98% | 66.88 | 66.20 | 67.45 | 67.47 | 66.58 | 66.58 | 4,608,924 | 00:50:03 |
From Dec 2022 to Dec 2024
By Colin Kellaher
Shares of Icosavax jumped nearly 50% in premarket trading Tuesday after the vaccine developer agreed to be acquired by pharmaceutical giant AstraZeneca in a deal worth up to $1.1 billion.
AstraZeneca is paying an initial $838 million, or $15 a share, in cash for Icosavax, a 43% premium to Tuesday's closing price of $10.49 for the Seattle company.
Icosavax said its investors also will receive non-tradable contingent value rights tied to future regulatory and sales milestones that are worth up to $5 a share in cash, bringing the total potential deal value to $20 a share, more than 90% above Tuesday's closing price.
The deal is slated to close in the first quarter of 2024.
Icosavax shares were recently up 49% to $15.59 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 12, 2023 06:10 ET (11:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
